FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib

LEXINGTON, Mass., Aug. 18, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA)...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials